Global PD-1 and PD-L1 Immunotherapy Market 2024 by Company, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global PD-1 and PD-L1 Immunotherapy market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
The Global Info Research report includes an overview of the development of the PD-1 and PD-L1 Immunotherapy industry chain, the market status of Solid Tumors (PD-1 inhibitor, PD-L1 inhibitor), Blood-related Tumors (PD-1 inhibitor, PD-L1 inhibitor), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of PD-1 and PD-L1 Immunotherapy.
Regionally, the report analyzes the PD-1 and PD-L1 Immunotherapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global PD-1 and PD-L1 Immunotherapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the PD-1 and PD-L1 Immunotherapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the PD-1 and PD-L1 Immunotherapy industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., PD-1 inhibitor, PD-L1 inhibitor).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the PD-1 and PD-L1 Immunotherapy market.
Regional Analysis: The report involves examining the PD-1 and PD-L1 Immunotherapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the PD-1 and PD-L1 Immunotherapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to PD-1 and PD-L1 Immunotherapy:
Company Analysis: Report covers individual PD-1 and PD-L1 Immunotherapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards PD-1 and PD-L1 Immunotherapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Solid Tumors, Blood-related Tumors).
Technology Analysis: Report covers specific technologies relevant to PD-1 and PD-L1 Immunotherapy. It assesses the current state, advancements, and potential future developments in PD-1 and PD-L1 Immunotherapy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the PD-1 and PD-L1 Immunotherapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
PD-1 and PD-L1 Immunotherapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe PD-1 and PD-L1 Immunotherapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of PD-1 and PD-L1 Immunotherapy, with revenue, gross margin and global market share of PD-1 and PD-L1 Immunotherapy from 2019 to 2024.
Chapter 3, the PD-1 and PD-L1 Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and PD-1 and PD-L1 Immunotherapy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of PD-1 and PD-L1 Immunotherapy.
Chapter 13, to describe PD-1 and PD-L1 Immunotherapy research findings and conclusion.
The Global Info Research report includes an overview of the development of the PD-1 and PD-L1 Immunotherapy industry chain, the market status of Solid Tumors (PD-1 inhibitor, PD-L1 inhibitor), Blood-related Tumors (PD-1 inhibitor, PD-L1 inhibitor), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of PD-1 and PD-L1 Immunotherapy.
Regionally, the report analyzes the PD-1 and PD-L1 Immunotherapy markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global PD-1 and PD-L1 Immunotherapy market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the PD-1 and PD-L1 Immunotherapy market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the PD-1 and PD-L1 Immunotherapy industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., PD-1 inhibitor, PD-L1 inhibitor).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the PD-1 and PD-L1 Immunotherapy market.
Regional Analysis: The report involves examining the PD-1 and PD-L1 Immunotherapy market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the PD-1 and PD-L1 Immunotherapy market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to PD-1 and PD-L1 Immunotherapy:
Company Analysis: Report covers individual PD-1 and PD-L1 Immunotherapy players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards PD-1 and PD-L1 Immunotherapy This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Solid Tumors, Blood-related Tumors).
Technology Analysis: Report covers specific technologies relevant to PD-1 and PD-L1 Immunotherapy. It assesses the current state, advancements, and potential future developments in PD-1 and PD-L1 Immunotherapy areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the PD-1 and PD-L1 Immunotherapy market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
PD-1 and PD-L1 Immunotherapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- PD-1 inhibitor
- PD-L1 inhibitor
- Solid Tumors
- Blood-related Tumors
- AstraZeneca
- Bristol-Myers Squibb
- F. Hoffmann-La Roche
- Merck
- Pfizer
- Roche
- Novartis
- Jiangsu HengRui Medicine
- Innovent
- Eli Lilly
- GlaxoSmithKline
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe PD-1 and PD-L1 Immunotherapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of PD-1 and PD-L1 Immunotherapy, with revenue, gross margin and global market share of PD-1 and PD-L1 Immunotherapy from 2019 to 2024.
Chapter 3, the PD-1 and PD-L1 Immunotherapy competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and PD-1 and PD-L1 Immunotherapy market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of PD-1 and PD-L1 Immunotherapy.
Chapter 13, to describe PD-1 and PD-L1 Immunotherapy research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of PD-1 and PD-L1 Immunotherapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of PD-1 and PD-L1 Immunotherapy by Type
1.3.1 Overview: Global PD-1 and PD-L1 Immunotherapy Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type in 2023
1.3.3 PD-1 inhibitor
1.3.4 PD-L1 inhibitor
1.4 Global PD-1 and PD-L1 Immunotherapy Market by Application
1.4.1 Overview: Global PD-1 and PD-L1 Immunotherapy Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Solid Tumors
1.4.3 Blood-related Tumors
1.5 Global PD-1 and PD-L1 Immunotherapy Market Size & Forecast
1.6 Global PD-1 and PD-L1 Immunotherapy Market Size and Forecast by Region
1.6.1 Global PD-1 and PD-L1 Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global PD-1 and PD-L1 Immunotherapy Market Size by Region, (2019-2030)
1.6.3 North America PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
1.6.4 Europe PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
1.6.6 South America PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Product and Solutions
2.1.4 AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product and Solutions
2.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 F. Hoffmann-La Roche
2.3.1 F. Hoffmann-La Roche Details
2.3.2 F. Hoffmann-La Roche Major Business
2.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
2.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 F. Hoffmann-La Roche Recent Developments and Future Plans
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck PD-1 and PD-L1 Immunotherapy Product and Solutions
2.4.4 Merck PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Merck Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Product and Solutions
2.5.4 Pfizer PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business
2.6.3 Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
2.6.4 Roche PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Roche Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis PD-1 and PD-L1 Immunotherapy Product and Solutions
2.7.4 Novartis PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Jiangsu HengRui Medicine
2.8.1 Jiangsu HengRui Medicine Details
2.8.2 Jiangsu HengRui Medicine Major Business
2.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product and Solutions
2.8.4 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Jiangsu HengRui Medicine Recent Developments and Future Plans
2.9 Innovent
2.9.1 Innovent Details
2.9.2 Innovent Major Business
2.9.3 Innovent PD-1 and PD-L1 Immunotherapy Product and Solutions
2.9.4 Innovent PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Innovent Recent Developments and Future Plans
2.10 Eli Lilly
2.10.1 Eli Lilly Details
2.10.2 Eli Lilly Major Business
2.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Product and Solutions
2.10.4 Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Eli Lilly Recent Developments and Future Plans
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product and Solutions
2.11.4 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 GlaxoSmithKline Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global PD-1 and PD-L1 Immunotherapy Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of PD-1 and PD-L1 Immunotherapy by Company Revenue
3.2.2 Top 3 PD-1 and PD-L1 Immunotherapy Players Market Share in 2023
3.2.3 Top 6 PD-1 and PD-L1 Immunotherapy Players Market Share in 2023
3.3 PD-1 and PD-L1 Immunotherapy Market: Overall Company Footprint Analysis
3.3.1 PD-1 and PD-L1 Immunotherapy Market: Region Footprint
3.3.2 PD-1 and PD-L1 Immunotherapy Market: Company Product Type Footprint
3.3.3 PD-1 and PD-L1 Immunotherapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global PD-1 and PD-L1 Immunotherapy Consumption Value and Market Share by Type (2019-2024)
4.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2024)
5.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
6.2 North America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
6.3 North America PD-1 and PD-L1 Immunotherapy Market Size by Country
6.3.1 North America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2030)
6.3.2 United States PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
6.3.3 Canada PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
6.3.4 Mexico PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
7.2 Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
7.3 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country
7.3.1 Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2030)
7.3.2 Germany PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7.3.3 France PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7.3.4 United Kingdom PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7.3.5 Russia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7.3.6 Italy PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
8.2 Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
8.3 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region
8.3.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2019-2030)
8.3.2 China PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.3 Japan PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.4 South Korea PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.5 India PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.7 Australia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
9.2 South America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
9.3 South America PD-1 and PD-L1 Immunotherapy Market Size by Country
9.3.1 South America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2030)
9.3.2 Brazil PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
9.3.3 Argentina PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
10.2 Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
10.3 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Country
10.3.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2030)
10.3.2 Turkey PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
10.3.4 UAE PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 PD-1 and PD-L1 Immunotherapy Market Drivers
11.2 PD-1 and PD-L1 Immunotherapy Market Restraints
11.3 PD-1 and PD-L1 Immunotherapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 PD-1 and PD-L1 Immunotherapy Industry Chain
12.2 PD-1 and PD-L1 Immunotherapy Upstream Analysis
12.3 PD-1 and PD-L1 Immunotherapy Midstream Analysis
12.4 PD-1 and PD-L1 Immunotherapy Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of PD-1 and PD-L1 Immunotherapy
1.2 Market Estimation Caveats and Base Year
1.3 Classification of PD-1 and PD-L1 Immunotherapy by Type
1.3.1 Overview: Global PD-1 and PD-L1 Immunotherapy Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type in 2023
1.3.3 PD-1 inhibitor
1.3.4 PD-L1 inhibitor
1.4 Global PD-1 and PD-L1 Immunotherapy Market by Application
1.4.1 Overview: Global PD-1 and PD-L1 Immunotherapy Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Solid Tumors
1.4.3 Blood-related Tumors
1.5 Global PD-1 and PD-L1 Immunotherapy Market Size & Forecast
1.6 Global PD-1 and PD-L1 Immunotherapy Market Size and Forecast by Region
1.6.1 Global PD-1 and PD-L1 Immunotherapy Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global PD-1 and PD-L1 Immunotherapy Market Size by Region, (2019-2030)
1.6.3 North America PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
1.6.4 Europe PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
1.6.6 South America PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
1.6.7 Middle East and Africa PD-1 and PD-L1 Immunotherapy Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business
2.1.3 AstraZeneca PD-1 and PD-L1 Immunotherapy Product and Solutions
2.1.4 AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 AstraZeneca Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product and Solutions
2.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 F. Hoffmann-La Roche
2.3.1 F. Hoffmann-La Roche Details
2.3.2 F. Hoffmann-La Roche Major Business
2.3.3 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
2.3.4 F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 F. Hoffmann-La Roche Recent Developments and Future Plans
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck PD-1 and PD-L1 Immunotherapy Product and Solutions
2.4.4 Merck PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Merck Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer PD-1 and PD-L1 Immunotherapy Product and Solutions
2.5.4 Pfizer PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business
2.6.3 Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
2.6.4 Roche PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Roche Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis PD-1 and PD-L1 Immunotherapy Product and Solutions
2.7.4 Novartis PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Jiangsu HengRui Medicine
2.8.1 Jiangsu HengRui Medicine Details
2.8.2 Jiangsu HengRui Medicine Major Business
2.8.3 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product and Solutions
2.8.4 Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Jiangsu HengRui Medicine Recent Developments and Future Plans
2.9 Innovent
2.9.1 Innovent Details
2.9.2 Innovent Major Business
2.9.3 Innovent PD-1 and PD-L1 Immunotherapy Product and Solutions
2.9.4 Innovent PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Innovent Recent Developments and Future Plans
2.10 Eli Lilly
2.10.1 Eli Lilly Details
2.10.2 Eli Lilly Major Business
2.10.3 Eli Lilly PD-1 and PD-L1 Immunotherapy Product and Solutions
2.10.4 Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Eli Lilly Recent Developments and Future Plans
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product and Solutions
2.11.4 GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 GlaxoSmithKline Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global PD-1 and PD-L1 Immunotherapy Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of PD-1 and PD-L1 Immunotherapy by Company Revenue
3.2.2 Top 3 PD-1 and PD-L1 Immunotherapy Players Market Share in 2023
3.2.3 Top 6 PD-1 and PD-L1 Immunotherapy Players Market Share in 2023
3.3 PD-1 and PD-L1 Immunotherapy Market: Overall Company Footprint Analysis
3.3.1 PD-1 and PD-L1 Immunotherapy Market: Region Footprint
3.3.2 PD-1 and PD-L1 Immunotherapy Market: Company Product Type Footprint
3.3.3 PD-1 and PD-L1 Immunotherapy Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global PD-1 and PD-L1 Immunotherapy Consumption Value and Market Share by Type (2019-2024)
4.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2024)
5.2 Global PD-1 and PD-L1 Immunotherapy Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
6.2 North America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
6.3 North America PD-1 and PD-L1 Immunotherapy Market Size by Country
6.3.1 North America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2030)
6.3.2 United States PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
6.3.3 Canada PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
6.3.4 Mexico PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
7.2 Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
7.3 Europe PD-1 and PD-L1 Immunotherapy Market Size by Country
7.3.1 Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2030)
7.3.2 Germany PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7.3.3 France PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7.3.4 United Kingdom PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7.3.5 Russia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
7.3.6 Italy PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
8.2 Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
8.3 Asia-Pacific PD-1 and PD-L1 Immunotherapy Market Size by Region
8.3.1 Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2019-2030)
8.3.2 China PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.3 Japan PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.4 South Korea PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.5 India PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
8.3.7 Australia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
9.2 South America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
9.3 South America PD-1 and PD-L1 Immunotherapy Market Size by Country
9.3.1 South America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2030)
9.3.2 Brazil PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
9.3.3 Argentina PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2030)
10.2 Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2030)
10.3 Middle East & Africa PD-1 and PD-L1 Immunotherapy Market Size by Country
10.3.1 Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2030)
10.3.2 Turkey PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
10.3.4 UAE PD-1 and PD-L1 Immunotherapy Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 PD-1 and PD-L1 Immunotherapy Market Drivers
11.2 PD-1 and PD-L1 Immunotherapy Market Restraints
11.3 PD-1 and PD-L1 Immunotherapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 PD-1 and PD-L1 Immunotherapy Industry Chain
12.2 PD-1 and PD-L1 Immunotherapy Upstream Analysis
12.3 PD-1 and PD-L1 Immunotherapy Midstream Analysis
12.4 PD-1 and PD-L1 Immunotherapy Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2025-2030) & (USD Million)
Table 5. AstraZeneca Company Information, Head Office, and Major Competitors
Table 6. AstraZeneca Major Business
Table 7. AstraZeneca PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 8. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. AstraZeneca Recent Developments and Future Plans
Table 10. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Major Business
Table 12. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 13. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Bristol-Myers Squibb Recent Developments and Future Plans
Table 15. F. Hoffmann-La Roche Company Information, Head Office, and Major Competitors
Table 16. F. Hoffmann-La Roche Major Business
Table 17. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 18. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. F. Hoffmann-La Roche Recent Developments and Future Plans
Table 20. Merck Company Information, Head Office, and Major Competitors
Table 21. Merck Major Business
Table 22. Merck PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 23. Merck PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Merck Recent Developments and Future Plans
Table 25. Pfizer Company Information, Head Office, and Major Competitors
Table 26. Pfizer Major Business
Table 27. Pfizer PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 28. Pfizer PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Pfizer Recent Developments and Future Plans
Table 30. Roche Company Information, Head Office, and Major Competitors
Table 31. Roche Major Business
Table 32. Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 33. Roche PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Roche Recent Developments and Future Plans
Table 35. Novartis Company Information, Head Office, and Major Competitors
Table 36. Novartis Major Business
Table 37. Novartis PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 38. Novartis PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Novartis Recent Developments and Future Plans
Table 40. Jiangsu HengRui Medicine Company Information, Head Office, and Major Competitors
Table 41. Jiangsu HengRui Medicine Major Business
Table 42. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 43. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Jiangsu HengRui Medicine Recent Developments and Future Plans
Table 45. Innovent Company Information, Head Office, and Major Competitors
Table 46. Innovent Major Business
Table 47. Innovent PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 48. Innovent PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Innovent Recent Developments and Future Plans
Table 50. Eli Lilly Company Information, Head Office, and Major Competitors
Table 51. Eli Lilly Major Business
Table 52. Eli Lilly PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 53. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Eli Lilly Recent Developments and Future Plans
Table 55. GlaxoSmithKline Company Information, Head Office, and Major Competitors
Table 56. GlaxoSmithKline Major Business
Table 57. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 58. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. GlaxoSmithKline Recent Developments and Future Plans
Table 60. Global PD-1 and PD-L1 Immunotherapy Revenue (USD Million) by Players (2019-2024)
Table 61. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players (2019-2024)
Table 62. Breakdown of PD-1 and PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in PD-1 and PD-L1 Immunotherapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 64. Head Office of Key PD-1 and PD-L1 Immunotherapy Players
Table 65. PD-1 and PD-L1 Immunotherapy Market: Company Product Type Footprint
Table 66. PD-1 and PD-L1 Immunotherapy Market: Company Product Application Footprint
Table 67. PD-1 and PD-L1 Immunotherapy New Market Entrants and Barriers to Market Entry
Table 68. PD-1 and PD-L1 Immunotherapy Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global PD-1 and PD-L1 Immunotherapy Consumption Value (USD Million) by Type (2019-2024)
Table 70. Global PD-1 and PD-L1 Immunotherapy Consumption Value Share by Type (2019-2024)
Table 71. Global PD-1 and PD-L1 Immunotherapy Consumption Value Forecast by Type (2025-2030)
Table 72. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024)
Table 73. Global PD-1 and PD-L1 Immunotherapy Consumption Value Forecast by Application (2025-2030)
Table 74. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 75. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 76. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 77. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 78. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
Table 79. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
Table 80. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 83. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 84. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 87. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 88. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 89. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 90. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2019-2024) & (USD Million)
Table 91. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2025-2030) & (USD Million)
Table 92. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 93. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 94. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 95. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 96. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
Table 97. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 99. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 100. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 101. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 102. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
Table 103. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
Table 104. PD-1 and PD-L1 Immunotherapy Raw Material
Table 105. Key Suppliers of PD-1 and PD-L1 Immunotherapy Raw Materials
Table 1. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2025-2030) & (USD Million)
Table 5. AstraZeneca Company Information, Head Office, and Major Competitors
Table 6. AstraZeneca Major Business
Table 7. AstraZeneca PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 8. AstraZeneca PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. AstraZeneca Recent Developments and Future Plans
Table 10. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Major Business
Table 12. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 13. Bristol-Myers Squibb PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. Bristol-Myers Squibb Recent Developments and Future Plans
Table 15. F. Hoffmann-La Roche Company Information, Head Office, and Major Competitors
Table 16. F. Hoffmann-La Roche Major Business
Table 17. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 18. F. Hoffmann-La Roche PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. F. Hoffmann-La Roche Recent Developments and Future Plans
Table 20. Merck Company Information, Head Office, and Major Competitors
Table 21. Merck Major Business
Table 22. Merck PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 23. Merck PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 24. Merck Recent Developments and Future Plans
Table 25. Pfizer Company Information, Head Office, and Major Competitors
Table 26. Pfizer Major Business
Table 27. Pfizer PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 28. Pfizer PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 29. Pfizer Recent Developments and Future Plans
Table 30. Roche Company Information, Head Office, and Major Competitors
Table 31. Roche Major Business
Table 32. Roche PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 33. Roche PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 34. Roche Recent Developments and Future Plans
Table 35. Novartis Company Information, Head Office, and Major Competitors
Table 36. Novartis Major Business
Table 37. Novartis PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 38. Novartis PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 39. Novartis Recent Developments and Future Plans
Table 40. Jiangsu HengRui Medicine Company Information, Head Office, and Major Competitors
Table 41. Jiangsu HengRui Medicine Major Business
Table 42. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 43. Jiangsu HengRui Medicine PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 44. Jiangsu HengRui Medicine Recent Developments and Future Plans
Table 45. Innovent Company Information, Head Office, and Major Competitors
Table 46. Innovent Major Business
Table 47. Innovent PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 48. Innovent PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 49. Innovent Recent Developments and Future Plans
Table 50. Eli Lilly Company Information, Head Office, and Major Competitors
Table 51. Eli Lilly Major Business
Table 52. Eli Lilly PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 53. Eli Lilly PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 54. Eli Lilly Recent Developments and Future Plans
Table 55. GlaxoSmithKline Company Information, Head Office, and Major Competitors
Table 56. GlaxoSmithKline Major Business
Table 57. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Product and Solutions
Table 58. GlaxoSmithKline PD-1 and PD-L1 Immunotherapy Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 59. GlaxoSmithKline Recent Developments and Future Plans
Table 60. Global PD-1 and PD-L1 Immunotherapy Revenue (USD Million) by Players (2019-2024)
Table 61. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players (2019-2024)
Table 62. Breakdown of PD-1 and PD-L1 Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3)
Table 63. Market Position of Players in PD-1 and PD-L1 Immunotherapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 64. Head Office of Key PD-1 and PD-L1 Immunotherapy Players
Table 65. PD-1 and PD-L1 Immunotherapy Market: Company Product Type Footprint
Table 66. PD-1 and PD-L1 Immunotherapy Market: Company Product Application Footprint
Table 67. PD-1 and PD-L1 Immunotherapy New Market Entrants and Barriers to Market Entry
Table 68. PD-1 and PD-L1 Immunotherapy Mergers, Acquisition, Agreements, and Collaborations
Table 69. Global PD-1 and PD-L1 Immunotherapy Consumption Value (USD Million) by Type (2019-2024)
Table 70. Global PD-1 and PD-L1 Immunotherapy Consumption Value Share by Type (2019-2024)
Table 71. Global PD-1 and PD-L1 Immunotherapy Consumption Value Forecast by Type (2025-2030)
Table 72. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024)
Table 73. Global PD-1 and PD-L1 Immunotherapy Consumption Value Forecast by Application (2025-2030)
Table 74. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 75. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 76. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 77. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 78. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
Table 79. North America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
Table 80. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 81. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 82. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 83. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 84. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
Table 85. Europe PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
Table 86. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 87. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 88. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 89. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 90. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2019-2024) & (USD Million)
Table 91. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value by Region (2025-2030) & (USD Million)
Table 92. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 93. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 94. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 95. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 96. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
Table 97. South America PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
Table 98. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2019-2024) & (USD Million)
Table 99. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Type (2025-2030) & (USD Million)
Table 100. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2019-2024) & (USD Million)
Table 101. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Application (2025-2030) & (USD Million)
Table 102. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2019-2024) & (USD Million)
Table 103. Middle East & Africa PD-1 and PD-L1 Immunotherapy Consumption Value by Country (2025-2030) & (USD Million)
Table 104. PD-1 and PD-L1 Immunotherapy Raw Material
Table 105. Key Suppliers of PD-1 and PD-L1 Immunotherapy Raw Materials
LIST OF FIGURES
Figure 1. PD-1 and PD-L1 Immunotherapy Picture
Figure 2. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type in 2023
Figure 4. PD-1 inhibitor
Figure 5. PD-L1 inhibitor
Figure 6. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application in 2023
Figure 8. Solid Tumors Picture
Figure 9. Blood-related Tumors Picture
Figure 10. Global PD-1 and PD-L1 Immunotherapy Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 11. Global PD-1 and PD-L1 Immunotherapy Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 12. Global Market PD-1 and PD-L1 Immunotherapy Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 13. Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Region (2019-2030)
Figure 14. Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Region in 2023
Figure 15. North America PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 16. Europe PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 17. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 18. South America PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 19. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 20. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players in 2023
Figure 21. PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 22. Global Top 3 Players PD-1 and PD-L1 Immunotherapy Market Share in 2023
Figure 23. Global Top 6 Players PD-1 and PD-L1 Immunotherapy Market Share in 2023
Figure 24. Global PD-1 and PD-L1 Immunotherapy Consumption Value Share by Type (2019-2024)
Figure 25. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Type (2025-2030)
Figure 26. Global PD-1 and PD-L1 Immunotherapy Consumption Value Share by Application (2019-2024)
Figure 27. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Application (2025-2030)
Figure 28. North America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 29. North America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 30. North America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Country (2019-2030)
Figure 31. United States PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 32. Canada PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 33. Mexico PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 34. Europe PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 35. Europe PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 36. Europe PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Country (2019-2030)
Figure 37. Germany PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 38. France PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 39. United Kingdom PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 40. Russia PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 41. Italy PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 42. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 43. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 44. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Region (2019-2030)
Figure 45. China PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 46. Japan PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 47. South Korea PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 48. India PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 49. Southeast Asia PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 50. Australia PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 51. South America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 52. South America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 53. South America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Country (2019-2030)
Figure 54. Brazil PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 55. Argentina PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 56. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 57. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 58. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Country (2019-2030)
Figure 59. Turkey PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 60. Saudi Arabia PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 61. UAE PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 62. PD-1 and PD-L1 Immunotherapy Market Drivers
Figure 63. PD-1 and PD-L1 Immunotherapy Market Restraints
Figure 64. PD-1 and PD-L1 Immunotherapy Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Immunotherapy in 2023
Figure 67. Manufacturing Process Analysis of PD-1 and PD-L1 Immunotherapy
Figure 68. PD-1 and PD-L1 Immunotherapy Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
Figure 1. PD-1 and PD-L1 Immunotherapy Picture
Figure 2. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type in 2023
Figure 4. PD-1 inhibitor
Figure 5. PD-L1 inhibitor
Figure 6. Global PD-1 and PD-L1 Immunotherapy Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 7. PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application in 2023
Figure 8. Solid Tumors Picture
Figure 9. Blood-related Tumors Picture
Figure 10. Global PD-1 and PD-L1 Immunotherapy Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 11. Global PD-1 and PD-L1 Immunotherapy Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 12. Global Market PD-1 and PD-L1 Immunotherapy Consumption Value (USD Million) Comparison by Region (2019 & 2023 & 2030)
Figure 13. Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Region (2019-2030)
Figure 14. Global PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Region in 2023
Figure 15. North America PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 16. Europe PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 17. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 18. South America PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 19. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 20. Global PD-1 and PD-L1 Immunotherapy Revenue Share by Players in 2023
Figure 21. PD-1 and PD-L1 Immunotherapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2023
Figure 22. Global Top 3 Players PD-1 and PD-L1 Immunotherapy Market Share in 2023
Figure 23. Global Top 6 Players PD-1 and PD-L1 Immunotherapy Market Share in 2023
Figure 24. Global PD-1 and PD-L1 Immunotherapy Consumption Value Share by Type (2019-2024)
Figure 25. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Type (2025-2030)
Figure 26. Global PD-1 and PD-L1 Immunotherapy Consumption Value Share by Application (2019-2024)
Figure 27. Global PD-1 and PD-L1 Immunotherapy Market Share Forecast by Application (2025-2030)
Figure 28. North America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 29. North America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 30. North America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Country (2019-2030)
Figure 31. United States PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 32. Canada PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 33. Mexico PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 34. Europe PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 35. Europe PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 36. Europe PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Country (2019-2030)
Figure 37. Germany PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 38. France PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 39. United Kingdom PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 40. Russia PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 41. Italy PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 42. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 43. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 44. Asia-Pacific PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Region (2019-2030)
Figure 45. China PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 46. Japan PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 47. South Korea PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 48. India PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 49. Southeast Asia PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 50. Australia PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 51. South America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 52. South America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 53. South America PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Country (2019-2030)
Figure 54. Brazil PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 55. Argentina PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 56. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Type (2019-2030)
Figure 57. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Application (2019-2030)
Figure 58. Middle East and Africa PD-1 and PD-L1 Immunotherapy Consumption Value Market Share by Country (2019-2030)
Figure 59. Turkey PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 60. Saudi Arabia PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 61. UAE PD-1 and PD-L1 Immunotherapy Consumption Value (2019-2030) & (USD Million)
Figure 62. PD-1 and PD-L1 Immunotherapy Market Drivers
Figure 63. PD-1 and PD-L1 Immunotherapy Market Restraints
Figure 64. PD-1 and PD-L1 Immunotherapy Market Trends
Figure 65. Porters Five Forces Analysis
Figure 66. Manufacturing Cost Structure Analysis of PD-1 and PD-L1 Immunotherapy in 2023
Figure 67. Manufacturing Process Analysis of PD-1 and PD-L1 Immunotherapy
Figure 68. PD-1 and PD-L1 Immunotherapy Industrial Chain
Figure 69. Methodology
Figure 70. Research Process and Data Source
